NCT01667263View on ClinicalTrials.gov

The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

June 1, 2012

Primary Completion Date

July 1, 2016

Study Completion Date

February 1, 2017

Conditions
Autoimmune Thrombocytopenia
Interventions
DRUG

All-trans retinoic acid

DRUG

Danazol

Trial Locations (5)

100044

Beijing Hospital, Ministry of Health, Beijing

Peking University People's Hospital, Peking University Insititute of Hematology, Beijing

Unknown

Beijing Tongren Hospital, Beijing

PLA Navy General Hospital, Beijing

Qilu Hospital, Shandong University, Jinan

All Listed Sponsors
collaborator

Beijing Municipal Science & Technology Commission

OTHER

collaborator

Beijing Hospital

OTHER_GOV

collaborator

Qilu Hospital of Shandong University

OTHER

collaborator

Navy General Hospital, Beijing

OTHER

collaborator

Beijing Tongren Hospital

OTHER

lead

Peking University People's Hospital

OTHER

NCT01667263 - The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia | Biotech Hunter | Biotech Hunter